Limb Girdle Muscular Dystrophy Treatment Market: By Dystrophy Type (Limb-girdle Muscular Dystrophy Type-A and Limb-girdle Muscular Dystrophy Type-B), By Treatment Type (Symptomatic Treatments, Molecular & Gene Therapy, Stem-Cell Transplantation, Exon Skipping, and Others), By End-user (Hospital, Ambulatory Centres, and Others), and Geography

Limb Girdle Muscular Dystrophy Treatment Market size was valued at USD XX million in 2023 and is poised to grow at an 4.9% CAGR from 2024 to 2030. Limb-Girdle Muscular Dystrophy (LGMD) is a clinically heterogeneous group of disorders presenting a spectrum of disease severity ranging from severe childhood-onset muscular dystrophy to adult-onset dystrophy including both dominant and recessive forms. The increasing prevalence along with increasing expenditure on healthcare will drive the demand for limb-girdle muscular dystrophy treatment. Additionally, growing R&D activities and the development of treatment for such a rare disease contribute to market revenue growth. Moreover, several pipeline drugs such as SRP-9003, GenPHSat, BBP-418 (ribitol), and LION-101 are expected to receive FDA approval and be launched in the market in the coming years, boosting the market.

Furthermore, growing awareness among the population and increasing government initiatives for disease awareness are raising the demand for preventive treatment, boosting the market. However, the lack of existed molecules in the market and limited number of drugs in the pipeline are the factors expected to restrain the market during the forecast period. Fundraising from public and private organizations and development of novel molecules for the limb girdle muscular dystrophy treatment are anticipated to create lucrative opportunity for the companies in the near future. However, Artificial Intelligence (AI) has the potential to revolutionize the LGMD treatment market by significantly impacting the drug development and design process, offering a glimmer of hope for future therapeutic breakthroughs.

Limb Girdle Muscular Dystrophy Treatment Market Key Players:

• In February 2022, Asklepios BioPharmaceutical, Inc., a subsidiary of Bayer AG, announced that the European Commission (EC) granted orphan drug status to AB-1003 (also known as LION-101) for the treatment of limb-girdle muscular dystrophy (LGMD)